
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is experiencing challenges with their clinical trial for ARD-101, which has been placed on hold by the FDA due to a QRS signal. Management has stated that a new trial will be required, and success for the company relies on understanding the cause of the signal, showing positive efficacy data, and securing a viable path for registration within their cash runway. Given the lack of clarity and uncertainties, it is prudent to remain neutral on Aardvark Therapeutics.
Bears say
Aardvark Therapeutics is currently facing significant risks due to pausing patient enrollment and dosing in its pivotal HERO trial due to reversible cardiac observations at above-target therapeutic doses. This could potentially lead to delays in obtaining regulatory approval and launching its product candidate ARD-101, as well as potential partnership and dilution risks. Without further clarity on the future prospects of ARD-101, it is difficult to estimate the company's potential valuation and outlook.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares